Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OCUL
OCULAR THERAPEUTIX, INC.
NASDAQ
$10.36
▼ DOWN 4.25% (-0.46)

KEY STATISTICS

Market Cap$2.27 B
52w High$16.44
52w Low$6.23
Dividend Yield—
Frequency—
P/E-7.30
Volume1.56M
Shares Out.218.96M

COMPANY

LEADERSHIP

Pravin U. Dugel
CHIEF EXECUTIVE
Pravin U. Dugel

COMPENSATION 2026

Salary$819,200
Stock Awards$18,608,000
Incentive Plan Pay$0
All Other Comp.$61,878
Total$35,946,958

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 25, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
325

PRICE TARGET

Target High$30.00
Target Low$25.00
Target Median$27.50
Target Consensus$27.50

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$14.32M
NOV
3
TUE

PRICE

$10.36 ▼ DOWN 4.25% (−$0.46)
$10.35$10.50$10.659:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.36

About Ocular Therapeutix, Inc.

https://www.ocutx.com ↗

Ocular Therapeutix, Inc. develops bioresorbable hydrogel-based eye therapies, including products for post-surgical inflammation, dry eye, and retinal diseases, through collaborations with Regeneron, AffaMed, and Mosaic Biosciences.

INDUSTRY

Biotechnology

A PRODUCT OCULAR THERAPEUTIX, INC. IS KNOWN FOR

DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg
DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg

DEXTENZA is an FDA-approved, physician-administered corticosteroid insert placed in the eye's punctum, delivering up to 30 days of dexamethasone to treat ocular inflammation, pain post-surgery, and allergic conjunctivitis.

COMPETITORS

COMPETITOR
ALC COMPARE
BHC COMPARE
EYPT COMPARE
GKOS COMPARE
KALA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$14.54M $23.88M ▲$10.79M ▼$13.47M ▲
Collaboration revenue$128K $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
116
LISTED HERE
18
RANKED BY POSITION SIZE
VTS.AX
0.00% · 6.7M
XSU.TO
0.07% · 5.2M
PJP
3.22% · 1.6M
XPH
1.76% · 954.2K
SCHA
0.04% · 834.8K
DFAS
0.05% · 655.9K
XRSG.L
0.07% · 188.4K
RSSL
0.07% · 98.3K
FESM
0.02% · 93.9K
SURI
0.97% · 81.1K
BBSC
0.07% · 52.1K
PILL
1.18% · 26.9K
TILT
0.00% · 9.3K
URTY
0.03% · 8.4K
RFLR
0.06% · 5.2K
TNXT
0.07% · 1.2K
USFMDN.MX
0.00% · 745
RESM
0.10% · 576

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.28%
HOLDERS
369
TOP 12 OF 369 · RANKED BY POSITION SIZE
Fmr LLC
32.8M sh · $322.53M
Deep Track Capital, LP
19.7M sh · $193.32M
Blackrock, Inc.
19.4M sh · $190.28M
Vr Adviser, LLC
13.2M sh · $153.86M
Summer Road LLC
12.6M sh · $147.05M
Avoro Capital Advisors LLC
12.5M sh · $123.14M
Vanguard Group Inc
11.6M sh · $140.52M
Blackrock Inc.
11.5M sh · $78.8M
Price T Rowe Associates Inc /Md/
7.6M sh · $74.86M
Tcg Crossover Management, LLC
6.1M sh · $71.51M
Citadel Advisors LLC
5.7M sh · $66.68M
Point72 Asset Management, L.P.
5.5M sh · $46.88M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF DEVELOPMENT OFFICER
Kaiser Peter
Sale · 3.0K shares
2026-08-24
★
OFFICER: CHIEF STRATEGY OFFICER
Nayak Sanjay
Sale · 1.9K shares
2026-08-24
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Heier Jeffrey S.
Sale · 3.3K shares
2026-08-24
★
DIRECTOR, OFFICER: SEE REMARKS
Dugel Pravin
Sale · 21.6K shares
2026-08-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 2
OVERWEIGHT 1
MARKET OUTPERFORM 1
9 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY Baird OUTPERFORM HC Wainwright & Co. BUY RBC Capital OUTPERFORM Needham BUY Clear Street BUY TD Cowen BUY Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
LQDA$67.69COMPARE
COGT$34.67COMPARE
EWTX$42.76COMPARE
RCUS$29.21COMPARE
QURE$48.72COMPARE
GPCR$47.37COMPARE
VRDN$23.08COMPARE